Miles Vaughan Williams

From WikiMD's Food, Medicine & Wellness Encyclopedia

Miles Vaughan Williams (1918–2016) was a renowned British pharmacologist who made significant contributions to the field of cardiology. He is best known for his development of the Vaughan Williams Classification, a system used to categorize antiarrhythmic agents.

Early Life and Education[edit | edit source]

Miles Vaughan Williams was born in 1918 in United Kingdom. He pursued his education at the University of Oxford, where he developed a keen interest in the field of pharmacology.

Career[edit | edit source]

After completing his education, Vaughan Williams embarked on a career in pharmacology. He worked extensively in the field of cardiology, focusing on the study of arrhythmias and the drugs used to treat them. His research led to the development of the Vaughan Williams Classification, a system that categorizes antiarrhythmic agents based on their mechanism of action.

Vaughan Williams Classification[edit | edit source]

The Vaughan Williams Classification is a system used to categorize antiarrhythmic agents. It was developed by Vaughan Williams in the 1970s and is still widely used today. The system classifies drugs into four main classes (I, II, III, IV) based on their mechanism of action. Each class is further divided into subclasses to provide a more detailed classification.

Legacy[edit | edit source]

Vaughan Williams' contributions to the field of pharmacology have had a lasting impact. His classification system has been instrumental in the development and understanding of antiarrhythmic drugs. His work has also influenced the treatment of cardiac arrhythmias, improving the quality of life for patients worldwide.

See Also[edit | edit source]

References[edit | edit source]


External Links[edit | edit source]

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD